Journal
PSYCHIATRY RESEARCH
Volume 230, Issue 2, Pages 200-204Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.psychres.2015.08.040
Keywords
Sarcosine; Schizophrenia; Metabolic syndrome
Categories
Funding
- Polish Ministry of Science and Higher Education [N402 268836]
- Healthy Ageing Research Center [REGPOT-2012-2013-1]
Ask authors/readers for more resources
This study was undertaken with the purpose to determine if there are changes in metabolic parameters during 6-month add-on treatment with sarcosine in patients with schizophrenia. This was a randomized double blind, placebo-controlled and parallel group study. Eligible participants were randomly assigned to receive 2 g of sarcosine (n=30) or placebo (n=29). Sarcosine was administered as supplementation to the ongoing antipsychotic treatment. Augmentation with sarcosine had no effect on any of the analyzed cardiometabolic parameters. Also, augmentation with sarcosine had no effect on any of the analyzed body composition parameters. This is the first randomized placebo-controlled study to examine the metabolic safety of sarcosine in patients with schizophrenia. Clinically, this observation is of high importance considering how prevalent are metabolic abnormalities in patients with schizophrenia. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available